TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in stem and progenitor cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Knowledge regarding diagnosis of MIH
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Change in gaming craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of CYP19 polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of skin GvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: The number of patients who progress within 14 days of initiation of Ectoin treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in intensity of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Two segment sensory block regression time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma glucose concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fluorescein staining scores of the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum hs-CRP levels (mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked in 6 minute walk test (meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries arrestment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amplitude integrated electroencephalogram (aEEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Implant stability measured by maximum torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change in 24-hour Urinary Oxalate Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of Subjects Remaining Seizure Free for 6 Consecutive Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With at Least One Treatment-emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of AMG 232
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Percentage (%) Change in Serum Urate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Serum Urate at 24hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal Xanthine Excretion at 0-24hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alcohol consumption measured in Standard Drink Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity (Matsuda index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum levels of ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily Blood Glucose Concentration Inpatient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Daily Blood Glucose Concentration After Hospital Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of SPS AFO wearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion at Day 21 after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uremia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Net adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Face-name Memory Test Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Object Location Association Memory Test Performance - Recognition Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI Betaweight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AGYW Patronage (Count)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AGYW Patronage (Proportion)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIVST Kit Uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of urinary stress incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Assessment of discomfort linked to urinary stress incontinence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of ILD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: fMRI neural activation patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major device related adverse cardiac and cerebrovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: CoreScore
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of stent implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate (average of 1 minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall adherence to the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decreased hyperkeratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of HCV Seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain through the visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Morphine Equivalent Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of protocol defined treatment or procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Median parasite clearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Surgical Fear Questionnaire (SFQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogue Scale (VAS)-Anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change in Liver Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective Tumor Response Rate (Complete or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absolute change of Wrinkle Severity Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of AUS and RT-PCR/RT-LAMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of AUS, FNAB, and RT-PCR/RT-LAMP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Baseline gene expression levels in lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of plasma endotoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trough Seated DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection rate of adenoma of proximal colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mood and Anxiety Symptom Questionnaire Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of recommendation statements achieving positive consensus
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of recommendation statements achieving negative consensus
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of recommendation statements achieving consensus for neutrality
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Modified Fatigue Severity Score (FSS-11)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quebec Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of withdrawing anticoagulation
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibition of STAT3 phosphorylation in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality Of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Skin reactions differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Discontinuation rate differences
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Radiation-related optic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of HRQOL questionnaire completion
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUClast of R- and S-verapamil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of R- and S-verapamil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of R- and S-verapamil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with ACR 20/50/70 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of percent cellular viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of infection, dehiscence and re-amputation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of debridements, revisional surgeries and days of stay in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum static respiratory pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory muscular endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: QCA late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in perspective-taking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in empathetic concern
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent-infant interactions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Physician guideline adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postprandial maximum concentration (Cmax) of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial Area under curve (AUC(0-4)) of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Columbia Suicide Severity Rating Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Human Serum Bactericidal Activity (hSBA)≥1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hSBA Geometric Mean Titers (GMTs) After the Last Dose of rMenB+OMV NZ Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of recurrent or persistent endogenous Cushing's syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in ESSDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25(OH)VitD level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathological examination of lung tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial artery dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uterine artery doppler measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Umbilical artery doppler measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Combined Response (Serological, Virological, Biochemical)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early postoperative graft failure
Endpoint domain: Mortality/survival
Primary endpoint: Deaths, Serious Adverse Events (SAEs) and AEs Leading to Discontinuation From Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Selected Grade 3/4 Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in psychophysiological markers for nociceptive responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment upper extremity part (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm and Hand Activity Inventory (CAHAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box& Block Test of Manual Dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician-Reported Submental Fat Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of articulated activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution/progression of foot ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Embryo quality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical treatment complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Considered a Clinical Cure at Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With All Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: change in IMCL content in the soleus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Half relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of pain medication used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline POP-Q measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid-negative Saliva Tests at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 meter gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean body mass (LBM)/Fat mass (FM) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcirculation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported 30-day Use of Alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported 30-day Use of Cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported 30-day Marijuana Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported 30-day Inhalant Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Lifetime Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Lifetime Cigarette Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Magnetic Resonance Spectroscopy (MRS) Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of Subjects Achieving a PASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total Fecal Bile Acid (BA) Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in rectal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in forehead skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in tympanic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes from baseline in laboratory evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes from baseline in ECG evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes from baseline in physical/neurological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of rotavirus VP7 and VP4 genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of food allergy treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 18-Month Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Overall Safety Score assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of patients erythema, scaling, and pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of collateral flow index (CFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency, quantity, and duration of viremia following vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of vaccinees who seroconvert to DENV-2 by study Day 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in prevalence of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Food Cravings
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Patients That Respond to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MACE rate (major adverse cardiac events)
Endpoint domain: Mortality/survival
Primary endpoint: Clinical course of primary headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Changes in Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score of knowledge, attitude, and self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: failure of sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in subjective assessment of ureter visualisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Bone Mineral Density at the Lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification of children at high risk of having Fanconi anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of Fanconi anemia patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Exercise Sessions Attended
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in tracheal aspirate bacterial density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in submental volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe Fixation of Mesh and Closure of Peritoneum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Survival at 1 year after UCB transplant
Endpoint domain: Mortality/survival
Primary endpoint: Change in 24-hour Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bleeding score (SMOG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: complete blood count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CFTR-dependant chlorate secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from birth to first oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of outpatient rehab stay
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Freedom From MALE at 6 Months
Endpoint domain: Mortality/survival